ADQ’s $740 Million Acquisition of Amoun Pharmaceutical Company

Wachtell, Lipton, Rosen & Katz acted as legal advisor to Bausch Health in the transaction.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that it and certain of its affiliates have entered into a definitive agreement to sell all of their equity interests in Amoun Pharmaceutical Company S.A.E. to Abu-Dhabi based ADQ, one of the region’s largest holding companies, for total gross consideration of approximately U.S. $740 million (including the assignment to the Purchaser of an intercompany loan granted by Bausch Health to Amoun), subject to certain adjustments.

Amoun is one of the largest and most recognized pharmaceutical companies in Egypt that manufactures, markets and distributes branded generics of human and animal health products.

Bausch Health Companies Inc. is a global company whose mission is to improve people’s lives with our health care products. The Company develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology.

Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC served as financial advisors to Bausch Health.

Wachtell, Lipton, Rosen & Katz advised Bausch Health with a team which included Avi A. Sutton (Picture).

Involved fees earner: Avi Sutton – Wachtell, Lipton, Rosen & Katz;

Law Firms: Wachtell, Lipton, Rosen & Katz;

Clients: Bausch Health Companies Inc. ;

Print Friendly, PDF & Email

Author: Martina Bellini